News

Novo Nordisk
Aug 07, 2024
Drug Development for Transthyretin Amyloidosis
In Canada, an active 66-year-old man with no signs or symptoms of heart failure is diagnosed with atrial fibrillation after experiencing several weeks of…
Read more
alnylam.png
Jun 24, 2024
Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 24, 2024-- Alnylam Pharmaceuticals, Inc.external link, opens in a new tab (Nasdaq: ALNY), the leading RNAi therapeutics…
Read more
Novo Nordisk
May 24, 2024
Impact of Semaglutide in Amyloid Positivity (ISAP)
OverviewISAP examines the effects of oral semaglutide, a glucagon-like protein-1 receptor agonist used for diabetes, on the build-up of proteins in the brain…
Read more
Novo Nordisk
Apr 15, 2024
Novo Nordisk gets grant for antibodies binding to human transthyretin for treating TTR amyloidosis
A recently granted patent (Publication Number: US11912759B2) discloses an antibody designed to bind to human transthyretin. The antibody comprises specific amino…
Read more
Subscribe to